Background
==========

The research on urolithiasis in children has not been as rigorously as that in adults \[[@b1-medscimonit-24-1924]\] and their management is somewhat different than for adults \[[@b2-medscimonit-24-1924]\]. There are several drug therapies available for urolithiasis. However, metabolic abnormalities play a key role in caliceal stones formation and recurrence \[[@b3-medscimonit-24-1924]\]. Hypocitraturia, hyperuricosuria, hypercalciuria, and hyperoxaluria are common metabolic abnormalities seen in children with caliceal stones \[[@b4-medscimonit-24-1924]\].

Supersaturation of solute formed in the urine leads to the formation of caliceal stones. Many parameters can be involved in the supersaturation of solutes in urine, such as pH. Uric acid has pKa ≤5.5, and it is solubilized at pH ≥5.5 \[[@b5-medscimonit-24-1924]\]. Increased urinary pH exacerbates the situation, and supersaturation helps prevent the formation of caliceal stones \[[@b6-medscimonit-24-1924]\]. For alkalization of the urine \[[@b7-medscimonit-24-1924]\], hypocitraturia treatment is recommended in pediatric urolithiasis \[[@b8-medscimonit-24-1924]\]. Citrate replacement is commonly recommended to decrease stone recurrence rates in children \[[@b9-medscimonit-24-1924]\].

Changes in diet of pediatric patients may help to manage hypocitraturia. Several foods contain citric acid and their intake is recommended to prevent caliceal stones formation. A high fluid intake prevents caliceal stones formation by decreasing supersaturation and citrate prevents caliceal stones formation by ionization of urinary calcium \[[@b10-medscimonit-24-1924]\]. Lemons, oranges, and grapes are recommended in pediatric urolithiasis \[[@b11-medscimonit-24-1924],[@b12-medscimonit-24-1924]\]. Lemonade has 110 mg/kg calcium and 490 g/kg citric acid. However, oranges have 11 g/kg citric acid and 420 mg/kg calcium. Therefore, lemonade is more often used than orange juice in treating urolithiasis \[[@b3-medscimonit-24-1924]\].

The objective of the study was to evaluate the effects of potassium citrate and lemonade supplementation on urinary parameters for 1-day urine collection in children with urolithiasis.

Material and Methods
====================

Ethics approval and consent to participate
------------------------------------------

The study was registered in the Research Registry (*[www.researchregistry](www.researchregistry)*), UID No.: researchregistry3648, dated 10 February 2017. The protocol (CL/Ur/PQ/14/17, dated 1 February 2017) was approved by the First People's Hospital of Tongxiang Review Board. The study adhered to the law of the P.R. China, CONSORT guidelines, and the 2013 Declaration of Helsinki. All patients signed an informed consent form regarding interventions and diagnosis before the commencement of the study. All data used and/or generated in the study are available from DCIOM files of the First People's Hospital of Tongxiang, China and the Hangzhou Amcare Women's and Children's Hospital, China.

Inclusion criteria
------------------

We included all patients 4--16 years old, with lower ureteral stones calculi and fragment (diagnosed by color Doppler ultrasound, GE Healthcare, USA), admitted to the Department of Pediatrics of the First People's Hospital of Tongxiang, China from 25 February 2017 to 1 November 2017 with severe colic pain. Patients who had stone size ≤12 mm were included in the trial. The demographical conditions of patients are reported in [Table 1](#t1-medscimonit-24-1924){ref-type="table"}.

Exclusion criteria
------------------

Excluded criteria were: absence of stones (diagnosed by color Doppler ultrasound), anatomical abnormalities, voiding dysfunction, severe hydronephrosis, only urinary tract infection, history of open ureteral surgery, younger than 4 years and older than 16 years, failure to provide informed consent, stone size greater than 12 mm and less than 5 mm, and treatment with diuretics.

Design
------

A total of 126 children with pediatric urolithiasis participated in this randomized, experimental, cross-over study. A CONSORT flow diagram of the study is presented in [Figure 1](#f1-medscimonit-24-1924){ref-type="fig"}.

Interventions
-------------

All enrolled children drank lemonade (2 mEq/kg/day citrate) in 3 divided doses for 5 days. After a 15-day washout period, all enrolled patients drank 2 mEq/kg/day of potassium citrate in 3 divided doses for 5 days \[[@b3-medscimonit-24-1924]\]. Total fluid intake including water was not more than 4 L/day.

Urinary parameters measurements
-------------------------------

On the sixth of the day of individual intervention, a 24-hour urine was collected and sent to the pathology laboratory for evaluation of pH, urine volume, citrate level, and uric acid level, as well as elemental magnesium, phosphorus, potassium, and sodium. Every child was evaluated at baseline, after drinking of lemonade and supplementation of potassium citrate (on the sixth day) \[[@b3-medscimonit-24-1924]\].

Statistical analysis
--------------------

Data are represented as mean ±SD of all. InStat (GraphPad, USA) was used for statistical analysis. Urinary parameters for 1-day urine collection measurements after each supplementation were compared with baseline using the Mann-Whitney test \[[@b13-medscimonit-24-1924]\] following Tukey post hoc test (considering critical value \[*q*\] \>3.328) \[[@b14-medscimonit-24-1924]\] at 95% confidence level.

Results
=======

Urine samples of 1 child in the potassium citrate group and 5 children in the lemonade group were lost to evaluation during the follow-up study. After potassium citrate supplementation, urine sodium level was decreased (*p*=0.0337; *q*=3.76) and pH of urine was increased (*p*=0.0118; *q*=4.389). However, after lemonade supplimentation, urine sodium level was not decreased (*p*=0.239) and pH of urine was not increased (*p*=0.253). Urine volume, citrate level, and uric acid level, as well as elemental magnesium, phosphorus, and potassium, remained unchanged after 5-day supplementation with potassium citrate or lemonade ([Table 2](#t2-medscimonit-24-1924){ref-type="table"}). Potassium citrate supplementation was more effective than lemonade ([Table 3](#t3-medscimonit-24-1924){ref-type="table"}).

Discussion
==========

This study was performed with lemonade and potassium citrate supplementation in 3 divided doses for 5 days. The advance non-surgical treatment available for upper-tract stones is ESWL (extracorporeal shock-wave lithotripsy) \[[@b15-medscimonit-24-1924]\]. ESWL therapy is the first-line therapy for pediatric urolithiasis but has a high cost of treatment and does not always prevent recurrence \[[@b16-medscimonit-24-1924]\]. Pediatric SWL is preferred for renal pelvic stones but not for caliceal stones \[[@b17-medscimonit-24-1924]\]. It is debatable whether diet plays a crucial role in urinary tract stone formation \[[@b18-medscimonit-24-1924]\]. However, oxalate, high protein, calcium, low liquid, and salt intakes can contribute to urinary tract stone formation \[[@b19-medscimonit-24-1924]\]. Citrate is responsible for inhibition of caliceal stones, and increased citrate urine excretion leads to caliceal stones in the urinary tract \[[@b20-medscimonit-24-1924]\]. Therefore, citrate supplementation is recommended in pediatric urolithiasis.

Potassium citrate supplementation improves pH of urine, decreases urine sodium level, and increases the risk of gastric discomfort and oropharyngeal discomfort. Potassium citrate binds with sodium in urine and decreases sodium level in urine, increases pH of urine, and ultimately reduces stone formation \[[@b21-medscimonit-24-1924]\]. These results were in line with available studies \[[@b11-medscimonit-24-1924],[@b12-medscimonit-24-1924],[@b20-medscimonit-24-1924]\]. Potassium citrate is effective in treatment of pediatric urolithiasis.

The cost of 2 lemons in China is not more than 5 ¥, which is the daily dosage \[[@b22-medscimonit-24-1924]\]. Lemonade has high patient acceptance and no adverse effects but did not increase urine volume or pH. Lemonade has low potassium content \[[@b23-medscimonit-24-1924]\] and is a poor alkalinizing agent \[[@b3-medscimonit-24-1924]\]. The treatment with lemonade has no any positive effects in pediatric urolithiasis \[[@b22-medscimonit-24-1924]\]. Lemonade treatment is an alternative for mild hypocitraturia patients who are unable to tolerate first-line therapy \[[@b24-medscimonit-24-1924]\] or for long-term prevention of recurrent pediatric urolithiasis \[[@b25-medscimonit-24-1924]\]. However, these results were not in line with the available longitudinal study (3-months) \[[@b22-medscimonit-24-1924]\], perhaps because the longitudinal studies were based on the incidence of symptomatic kidney stones as the main outcome measure \[[@b25-medscimonit-24-1924]\], whereas the present study was a short-term study (5 days) and the objective was to assess effects of beverages on urinary parameters. Lemonade is not a good alternative to potassium citrate in pediatric urolithiasis.

Our study has certain limitations: the combination of lemonade and potassium citrate supplementation was not tried, a longitudinal study was not performed, we did not consider family history of stone formations, and unmeasured or residual confounding factors were not evaluated.

Conclusions
===========

This randomized, experimental, cross-over study concluded that potassium citrate supplementation is a good therapy for preventing pediatric urolithiasis, with acceptable adverse effects. Further research is needed to assess effects of longer-duration interventions.
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###### 

The demographical conditions of enrolled patients.

  Characteristics                                       Patients        
  ----------------------------------------------------- --------------- ----------
  Sample size                                           126             
  Age                                                   9.85±3.24       
  Sex                                                   Boy             87 (69)
  Girl                                                  39 (31)         
  Weight (kg)                                           25.1±3          
  Height (cm)                                           138.24±5.6      
  Stone size (mm)                                       5--10           99 (79)
  11--12                                                27 (21)         
  Position of stone                                     Dominant side   58 (46)
  Non-dominant side                                     68 (54)         
  Stone location in ureter                              Lower           65 (52)
  Upper                                                 49 (38)         
  Middle                                                12 (10)         
  Ethnicity                                             Chinese         124 (98)
  Non-Chinese                                           2 (2)           
  History of ceftriaxone and/or cephalothin treatment   15 (12)         

Continuous data were represented as mean ±SD and constant data were represented as a number (percentage).

###### 

Urinary parameters for one-day urine collection measurements.

  Parameters           Baseline        After supplementation                                 
  -------------------- --------------- ----------------------- --------------- ------- ----- -------
  Sample size          126             125                     p               121     p     
  Urine volume (L)     Min             0.75                    0.74            0.845   0.8   0.586
  Max                  2.7             2.72                    1.12                          
  Mean ±SD             1.45±0.49       1.46±0.5                1.56±1                        
  Citrate (mg)         Min             70                      71              0.898   69    0.978
  Max                  1534            1537                    1533                          
  Mean ±SD             879.02±464.27   879.03±465.85           880.38±471.85                 
  Urate (mg)           Min             101                     99              0.858   97    0.655
  Max                  1021            1200                    1195                          
  Mean ±SD             701.83±321.26   697.71±322.14           684.42±325.23                 
  Magnesium (mEq/L)    Min             35                      33              0.848   32    0.929
  Max                  111             110                     109                           
  Mean ±SD             64.7±21.7       64.18±21.56             64.33±21.27                   
  Phosphorus (mEq/L)   Min             101                     99              0.863   97    0.688
  Max                  1201            1200                    1195                          
  Mean ±SD             699.94±321.83   695.85±322.76           684.42±325.23                 
  Potassium (mEq/L)    Min             19                      19              0.056   15    0.142
  Max                  81              81                      77                            
  Mean ±SD             39.02±17.43     40.94±16.18             36.54±17.09                   

SA -- statistical analysis with respect to the baseline; Min -- minimum; Max -- maximum.

Mann-Whitney test following Tukey *post hoc* test was performed for statistical analysis. *p*\<0.05 and *q*\>3.328 values were considered for significant difference.

###### 

The treatment-emergent effects.

  Characteristics                                Baseline[\#](#tfn7-medscimonit-24-1924){ref-type="table-fn"}   After supplementation                                      
  ---------------------------------------------- -------------------------------------------------------------- ----------------------- ---------- -------- -------------- -------
  Sample size                                    126                                                            125                     p          q        121            p
  Gastric discomfort                             1 (1)                                                          7 (6)                   0.4855     N/A      1(1)           0.997
  Oropharyngeal discomfort                       0 (0)                                                          9 (7)                   N/P        N/P      1(1)           N/P
  Number of hospital visits for pain in 5 days   3.17±0.37                                                      2.84±0.37               \<0.0001   12.084   3.05±0.36      0.119
  Analgesic use (Diclofenac sodium, mg)          390.08±116.96                                                  191.6±60.82             \<0.0001   29.199   376.03±103.1   0.401
  Numbers of colic pain episodes/day             1.59±0.8                                                       1.6±0.8                 0.895      N/A      1.48±0.65      0.594

Continuous data were represented as mean ±SD and constant data were represented as a number (percentage).

SA -- statistical analysis with respect to the baseline.

Mann-Whitney test following Tukey *post hoc* test was performed for statistical analysis. *p*\<0.05 and *q*\>3.328 values were considered for significant difference. N/A -- not applicable, N/P -- not possible;

Data of five days without treatment.
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